Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFAMOSI
2024-511625-55-00Phase 4Authorised
- Sponsor
- University Medical Center Mainz
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of afatinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Medical Center Mainz. Primary endpoint: Time to EGFR-TKI failure within 24 months for afatinib followed by osimertinib in T790M-positive group vs osimertinib. Planned start Jun 2024; status: authorised.
02
Drugs
afatinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511625-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511625-55-00.